These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38630166)

  • 1. Valuing the SF-6Dv2 in the capital of Iran using a discrete choice experiment with duration.
    Daroudi R; Zeraati H; Poder TG; Norman R; Olyaeemanesh A; Sari AA; Ameri H
    Qual Life Res; 2024 Jul; 33(7):1853-1863. PubMed ID: 38630166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Valuing the SF-6Dv2 Classification System in the United Kingdom Using a Discrete-choice Experiment With Duration.
    Mulhern BJ; Bansback N; Norman R; Brazier J;
    Med Care; 2020 Jun; 58(6):566-573. PubMed ID: 32221100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Creating an SF-6Dv2 social value set for New Zealand.
    Sullivan T; McCarty G; Ombler F; Turner R; Mulhern B; Hansen P
    Soc Sci Med; 2024 Aug; 354():117073. PubMed ID: 38959817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valuing SF-6Dv2 in Australia Using an International Protocol.
    Mulhern B; Norman R; Brazier J
    Pharmacoeconomics; 2021 Oct; 39(10):1151-1162. PubMed ID: 34250578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension.
    Wu J; Xie S; He X; Chen G; Bai G; Feng D; Hu M; Jiang J; Wang X; Wu H; Wu Q; Brazier JE
    Pharmacoeconomics; 2021 May; 39(5):521-535. PubMed ID: 33598860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing a New Version of the SF-6D Health State Classification System From the SF-36v2: SF-6Dv2.
    Brazier JE; Mulhern BJ; Bjorner JB; Gandek B; Rowen D; Alonso J; Vilagut G; Ware JE;
    Med Care; 2020 Jun; 58(6):557-565. PubMed ID: 32412942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychometric properties of the SF-6Dv2 in an Iranian breast cancer population.
    Nahvijou A; Safari H; Ameri H
    Breast Cancer; 2021 Jul; 28(4):937-943. PubMed ID: 33666840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey.
    Xie S; Wang D; Wu J; Liu C; Jiang W
    Health Qual Life Outcomes; 2022 Jun; 20(1):96. PubMed ID: 35710429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Norms for SF-6Dv2 and EQ-5D-5L in China.
    Xie S; Wu J; Xie F
    Appl Health Econ Health Policy; 2022 Jul; 20(4):573-585. PubMed ID: 35132573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer population norms using a new value set for the SF-6Dv2 based on the preferences of patients with breast or colorectal cancer in Quebec.
    Touré M; Sfairy SM; Bédard SK; McFadden N; Hanel R; Lemay F; He J; Pavic M; Poder TG
    Qual Life Res; 2024 Jun; 33(6):1605-1619. PubMed ID: 38642218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SF-6Dv2 preference value set for health utility in food allergy.
    Dufresne É; Poder TG; Samaan K; Lacombe-Barrios J; Paradis L; Des Roches A; Bégin P
    Allergy; 2021 Jan; 76(1):326-338. PubMed ID: 32533705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative performance and mapping algorithms between EQ-5D-5L and SF-6Dv2 among the Chinese general population.
    Xie S; Wu J; Chen G
    Eur J Health Econ; 2024 Feb; 25(1):7-19. PubMed ID: 36709458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in health utilities between cancer patients and the general population: The case of Quebec using the SF-6Dv2.
    Touré M; Poder TG
    Soc Sci Med; 2024 Jun; 351():117001. PubMed ID: 38805836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting SF-6Dv2 utility scores for chronic low back pain using the Oswestry Disability Index and Roland-Morris Disability Questionnaire.
    Poder TG; Carrier N
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):105-110. PubMed ID: 32275183
    [No Abstract]   [Full Text] [Related]  

  • 15. Discrete choice experiment with duration versus time trade-off: a comparison of test-retest reliability of health utility elicitation approaches in SF-6Dv2 valuation.
    Xie S; Wu J; Chen G
    Qual Life Res; 2022 Sep; 31(9):2791-2803. PubMed ID: 35610406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population.
    McDool E; Mukuria C; Brazier J
    Pharmacoeconomics; 2021 Aug; 39(8):929-940. PubMed ID: 34043147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping the cancer-specific FACT-B onto the generic SF-6Dv2.
    Nahvijou A; Safari H; Yousefi M; Rajabi M; Arab-Zozani M; Ameri H
    Breast Cancer; 2021 Jan; 28(1):130-136. PubMed ID: 32712768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the monetary value of a Quality-Adjusted Life-Year in Quebec.
    Kouakou CRC; He J; Poder TG
    Eur J Health Econ; 2024 Jul; 25(5):787-811. PubMed ID: 37656261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valuing Health State: An EQ-5D-5L Value Set for Ethiopians.
    Welie AG; Gebretekle GB; Stolk E; Mukuria C; Krahn MD; Enquoselassie F; Fenta TG
    Value Health Reg Issues; 2020 Sep; 22():7-14. PubMed ID: 31683254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deciding Between SF-6Dv2 Health States: A Think-Aloud Study of Decision-Making Strategies Used in Discrete Choice Experiments.
    Broderick L; Bjorner JB; Lauher-Charest M; White MK; Kosinski M; Mulhern B; Brazier J
    Value Health; 2022 Dec; 25(12):2034-2043. PubMed ID: 36064513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.